2 394

Cited 24 times in

Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer

Authors
 Yoon Jae Kim  ;  Seungmin Bang  ;  Jeong Youp Park  ;  Seung Woo Park  ;  Jae Bock Chung  ;  Si Young Song 
Citation
 CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.63(3) : 529-533, 2009 
Journal Title
 CANCER CHEMOTHERAPY AND PHARMACOLOGY 
ISSN
 0344-5704 
Issue Date
2009
MeSH
Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Deoxycytidine/analogs & derivatives* ; Deoxycytidine/therapeutic use ; Drug Resistance, Neoplasm ; Female ; Fluorouracil/administration & dosage ; Humans ; Male ; Middle Aged ; Paclitaxel/administration & dosage ; Pancreatic Neoplasms/drug therapy*
Keywords
Pancreatic cancer ; Paclitaxel ; 5-Fluorouracil ; Gemcitabine
Abstract
PURPOSE: There is no effective salvage regimen for failed gemcitabine-based chemotherapy. This study evaluated the efficacy and toxicity of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. METHODS: Between January 2004 and December 2007, 28 patients with pancreatic cancer previously treated with gemcitabine-based chemotherapy were enrolled. 5-Fluorouracil 1,000 mg/m(2) was infused (days 1, 2, and 3) and paclitaxel 175 mg/m(2) (day 1) was administered every 4 weeks. The primary endpoint of this study was efficacy and toxicity and the secondary endpoint was time to progression and overall survival. RESULTS: A total of 75 cycles were given, for a mean of 2.68 cycles per patient. The response could be evaluated in 20 patients. Two patients (10%) obtained a partial response, and four patients (20%) had stable disease. The median time to progression and overall survival was 2.5 and 7.6 months, respectively. Grade 3/4 hematological toxicity included neutropenia in six patients (21.4%), anemia in one (3.6%), and thrombocytopenia in one (3.6%). One (3.6%) patient experienced grade 4 neuropathy, and two (7.2%) patients experienced grade 3 diarrhea. CONCLUSION: The 5-fluorouracil and paclitaxel combination treatment seems to be effective in patients with advanced pancreatic cancer that did not respond to a gemcitabine-based regimen.
Full Text
http://link.springer.com/article/10.1007%2Fs00280-008-0822-7
DOI
10.1007/s00280-008-0822-7
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Yoon Jae(김윤재)
Park, Seung Woo(박승우) ORCID logo https://orcid.org/0000-0001-8230-964X
Park, Jeong Youp(박정엽) ORCID logo https://orcid.org/0000-0003-0110-8606
Bang, Seungmin(방승민) ORCID logo https://orcid.org/0000-0001-5209-8351
Song, Si Young(송시영) ORCID logo https://orcid.org/0000-0002-1417-4314
Chung, Jae Bock(정재복)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/103377
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links